TRCT
AYTU icon

Tower Research Capital (TRC)’s AYTU BioPharma AYTU Stock Holding History

Tower Research Capital (TRC)’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.8K Buy
2,232
+668
+43% +$1.58K ﹤0.01% 4342
2026
Q1 		$4.27K Sell
1,564
-149
-9% -$381 ﹤0.01% 4215
2025
Q4 		$4.45K Sell
1,713
-2,610
-60% -$5.85K ﹤0.01% 4217
2025
Q3 		$8.13K Buy
4,323
+1,785
+70% +$4.13K ﹤0.01% 4064
2025
Q2 		$5.53K Sell
2,538
-2,153
-46% -$3.34K ﹤0.01% 4178
2025
Q1 		$5.63K Buy
4,691
+2,069
+79% +$3.01K ﹤0.01% 4104
2024
Q4 		$4.46K Buy
2,622
+1,149
+78% +$2.1K ﹤0.01% 4459
2024
Q3 		$3.46K Sell
1,473
-489
-25% -$1.27K ﹤0.01% 4842
2024
Q2 		$5.73K Sell
1,962
-1,064
-35% -$3.21K ﹤0.01% 4658
2024
Q1 		$9.2K Buy
3,026
+743
+33% +$2.13K ﹤0.01% 3882
2023
Q4 		$6.48K Sell
2,283
-3,471
-60% -$9.56K ﹤0.01% 4735
2023
Q3 		$15.5K Sell
5,754
-1,418
-20% -$2.48K ﹤0.01% 3607
2023
Q2 		$11.5K Buy
7,172
+5,446
+316% +$10.7K ﹤0.01% 3970
2023
Q1 		$4K Buy
1,726
+113
+7% +$331 ﹤0.01% 5044
2022
Q4 		$6K Sell
1,613
-892
-36% -$3.36K ﹤0.01% 4680
2022
Q3 		$10K Buy
2,505
+424
+20% +$3.22K ﹤0.01% 4510
2022
Q2 		$29K Buy
2,081
+710
+52% +$9.09K ﹤0.01% 3398
2022
Q1 		$30K Sell
1,371
-85
-6% -$2.11K ﹤0.01% 3136
2021
Q4 		$39K Buy
1,456
+1,379
+1,791% +$59.6K ﹤0.01% 2964
2021
Q3 		$4K Sell
77
-462
-86% -$34.7K ﹤0.01% 4950
2021
Q2 		$54K Buy
539
+468
+659% +$54.9K ﹤0.01% 2963
2021
Q1 		$11K Sell
71
-57
-45% -$9.05K ﹤0.01% 4300
2020
Q4 		$15K Buy
128
+19
+17% +$3.46K ﹤0.01% 4039
2020
Q3 		$26K Buy
109
+92
+541% +$23.6K ﹤0.01% 3771
2020
Q2 		$5K Buy
+17
New +$5.15K ﹤0.01% 4261
2019
Q3 		– Sell
-4
Closed -$2K – 4078
2019
Q2 		$2K Buy
+4
New +$1.52K ﹤0.01% 3234

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Crown Advisors Management Larkspur, California $182M AUM 103.97% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Tower Research Capital (TRC)'s AYTU Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its AYTU BioPharma (AYTU) stake by 43% in Q2 2026, buying an estimated $1.58K and bringing the position to 2,232 shares worth $4.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4342.

Tower Research Capital (TRC) first reported a position in AYTU in Q2 2019 and has held it in 26 quarters since. The position peaked at $54K in Q2 2021. 38 funds tracked by Wall St. Rank hold AYTU as of Q2 2026.

  • Tower Research Capital (TRC) held 2,232 shares of AYTU BioPharma worth $4.8K as of Q2 2026.
  • Tower Research Capital (TRC) bought 668 AYTU BioPharma shares in Q2 2026, an estimated $1.58K.
  • AYTU BioPharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4342 holding.
  • Tower Research Capital (TRC) first reported a position in AYTU BioPharma in Q2 2019 and has held it in 26 quarters since.
  • Tower Research Capital (TRC)'s AYTU BioPharma position peaked at $54K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.